Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow …
T Ueda, T Maeda, S Kusakabe, J Fujita… - International Journal of …, 2019 - Springer
A conditioning regimen with fludarabine and myeloablative dose of busulfan (FLU/BU4) has
been commonly used in allogeneic hematopoietic cell transplantation (allo-HCT). However …
been commonly used in allogeneic hematopoietic cell transplantation (allo-HCT). However …
Low-dose total body irradiation promotes T-cells donor chimerism in reduced-intensity/non-myeloablative allogeneic stem cell transplant with post-transplant …
N Shah, J Cioccio, K Rakszawski… - Leukemia …, 2022 - pubmed.ncbi.nlm.nih.gov
Low-dose total body irradiation promotes T-cells donor chimerism in reduced-intensity/non-myeloablative
allogeneic stem cell transplant with post-transplant cyclophosphamide Low-dose total body …
allogeneic stem cell transplant with post-transplant cyclophosphamide Low-dose total body …
Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk …
T Bernal, M Diez-Campelo, V Godoy, S Rojas… - Leukemia Research, 2014 - Elsevier
We evaluated the impact of detection of minimal residual disease by flow cytometry
(FCMRD) and CD3 chimerism in relapse in a cohort of 87 patients with acute myeloid …
(FCMRD) and CD3 chimerism in relapse in a cohort of 87 patients with acute myeloid …
Complete donor chimerism is a prerequisite for the effect of Predicted Indirectly ReCognizable HLA Epitopes (PIRCHE) on acute graft-versus-host disease
KA Thus, RA de Weger, TA de Hoop, VE Boers Trilles… - Chimerism, 2014 - Taylor & Francis
Predicted indirectly recognizable HLA epitopes (PIRCHE) computationally predict donor T-
cell recognition of mismatched-HLA derived peptides following allogeneic haematopoietic …
cell recognition of mismatched-HLA derived peptides following allogeneic haematopoietic …
[HTML][HTML] Мониторинг химеризма после трансплантации аллогенных гемопоэтических стволовых клеток
ДС Дубняк, НВ Рисинская, МЮ Дроков… - …, 2022 - cyberleninka.ru
Трансплантация аллогенных гемопоэтических стволовых клеток является одним из
эффективных методовлечения пациентов с заболеваниями системы крови. Среди …
эффективных методовлечения пациентов с заболеваниями системы крови. Среди …
[HTML][HTML] Donor CD3+ lymphocyte infusion after reduced intensity conditioning allogeneic stem cell transplantation: Single-center experience
J El-Cheikh, R Crocchiolo, S Furst, P Ladaique… - Experimental …, 2013 - Elsevier
Donor lymphocyte infusions (DLI) can induce remission in patients with hematologic
malignancies who relapse after allogeneic stem cell transplantation. However, graft-vs-host …
malignancies who relapse after allogeneic stem cell transplantation. However, graft-vs-host …
[HTML][HTML] 供者来源CD19-CAR-T 细胞在异基因造血干细胞移植后复发B 细胞恶性肿瘤中的应用
金鑫， 武日茂， 赵明峰 - Chinese Journal of Hematology, 2016 - ncbi.nlm.nih.gov
恶性B 细胞疾病包括急性和慢性B 淋巴细胞白血病(BALL, B-CLL) 以及一些淋巴瘤亚型.
除了弥漫性大B 细胞淋巴瘤(DLBCL), 对于大多数患这些疾病的成人患者来说 …
除了弥漫性大B 细胞淋巴瘤(DLBCL), 对于大多数患这些疾病的成人患者来说 …
Impact of T-cell chimerism on relapse after cord blood transplantation for hematological malignancies: Nagoya Blood and Marrow Transplantation Group study
E Yokohata, Y Kuwatsuka, H Ohashi… - Bone marrow …, 2017 - nature.com
Hematopoietic stem cell transplantation (HSCT) is the only curative therapy for
hematological malignancies. Cord blood is an alternative stem cell source when no suitable …
hematological malignancies. Cord blood is an alternative stem cell source when no suitable …
Mixed T cell chimerism in bone marrow at day+ 30 after allogeneic stem cell transplantation: correlation with acute GVHD grades III–IV and no impact on relapse and …
S Guidotti, S Bassi, A Rossi, E Borotti… - European Journal of …, 2022 - Wiley Online Library
Objectives Early chimerism analysis is important to assess engraftment in allogeneic
hematopoietic stem cell transplantations. Methods We retrospectively investigated the …
hematopoietic stem cell transplantations. Methods We retrospectively investigated the …
[HTML][HTML] BEAM-campath allogeneic stem cell transplant for patients with relapsed/refractory lymphoma: high incidence of long-term mixed donor-recipient chimerism …
C Burney, K Wadhera, P Breslin, R Pearce… - Biology of Blood and …, 2020 - Elsevier
ABSTRACT BiCNU (carmustine), etoposide, Ara-C, melphalan (BEAM) and Campath
conditioning was developed to reduce the high transplant-related mortality in patients with …
conditioning was developed to reduce the high transplant-related mortality in patients with …